Statistical Considerations for Digitally-Derived Endpoints in Clinical Trials

Join the Food and Drug Administration (FDA) for a virtual public workshop, convened by the Duke-Margolis Institute for Health Policy under a cooperative agreement with the FDA, to discuss statistical considerations for digitally-derived endpoints in clinical trials for drug and biological products....

Join the Food and Drug Administration (FDA) for a virtual public workshop, convened by the...

Read More

Innovation in Quantitative Medicine Summit

The Duke-Margolis Institute for Health Policy and the U.S. Food and Drug Administration's Quantitative Medicine Center of Excellence will co-convene a virtual workshop on September 1, 2026, to inform the establishment of the Quantitative Medicine Innovation Network (QMIN). The QMIN will bring...

The Duke-Margolis Institute for Health Policy and the U.S. Food and Drug Administration's...

Read More

RISE to the Challenge: Statistical Considerations for Rare Disease Clinical Investigations

WASHINGTON, DC

This public workshop, co-convened by Duke Margolis and the FDA Rare Disease Innovation Hub, will explore statistical considerations in the design, conduct, and analysis of clinical investigations for rare disease medical products. The small patient populations inherent to rare disease present unique...

This public workshop, co-convened by Duke Margolis and the FDA Rare Disease Innovation Hub, will...

Read More